Stronger Blood Cancer Drug Appears Successful
Part of the treatment for especially severe cancers of the blood is to destroy all the cells in the bone marrow that are responsible for making both the good and bad parts of the blood with radiation therapy.
Missing Leukemias Found
A recent study shows just how fragile the relationship between reported news and truth can be. The recent drop in reported myeloid leukemias over the last decade may be just a classification error.
No Bone Drug Better Than Another
Multiple myeloma is a cancer of the blood cells. It grows in the bone marrow, and can cause long bones like the thigh bone (femur) and bones in the spine to break. Drug therapy with a class of drugs can help to prevent these fractures.
Revlimid and Risk of New Cancers
The U.S. Food and Drug Administration (FDA) is informing the public of an increased risk of second primary malignancies (new types of cancer) in patients with newly-diagnosed multiple myeloma who received Revlimid ( lenalidomide ).
CT Scan For Bone Cancer Triples Accuracy
Traditionally a series of x-rays of all of the major bones in the body are used to detect myeloid myeloma , a process known as a radiographic skeletal survey. Yet in some areas, especially Europe, whole body CT is beginning to gain favor as testing indicates it is a more effective and thorough exam for measuring bone involvement in multiple myelomas , a bone-based form of leukemia. Ask your oncologist about whole body CT scanning for multiple myeloma . A formal comparison between the two imaging technologies was presented at the American Roentgen Ray Society's annual meeting by ...
Cancer Rx Linked to Second Cancers
Health Canada, the Canadian version of the U.S. Food & Drug Administration (FDA), has issued an alert regarding the medication REVLIMID ( lenalidomide ) that's used to treat multiple myeloma .
FDA Approves Subcutaneous Administration of Takeda Drug Velcade
The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application ( sNDA ) for Velcade ( bortezomib ).
Keys to Unlocking Multiple Myeloma Resistance
People living with the blood cancer multiple myeloma typically take two drugs in combination. The problem is these drugs don't work with every person and tend to fade in effectiveness over time.
Merck Announces Multiple Myeloma Drug Trial Results
Merck announced today that a Phase III study of Zolinza ( vorinostat ), for investigational use in combination with bortezomib in patients with progressive multiple myeloma , met its primary endpoint, demonstrating a 23 percent reduction in the risk of progression compared to the standard therapy of bortezomib (p=0.01).
Getting Beyond Cancer Drug Resistance
Some cancers respond well to chemotherapy in the beginning. After some time, though, the therapy may stop working because of a condition known as acquired drug resistance (ADR). Doctors are gaining ground in understanding why this resistance happens.